Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions.

Pesarini G, Ariotti S, Ribichini F.

Interv Cardiol. 2014 Apr;9(2):94-101. doi: 10.15420/icr.2011.9.2.94.

2.

Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome.

Shakoor MT, Ayub S, Dhakam S.

Int J Cardiol Heart Vessel. 2014 Mar 19;3:64-67. doi: 10.1016/j.ijchv.2014.03.007. eCollection 2014 Jun.

3.

Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?

Iannetta L, Puddu PE, Cuturello D, Saladini A, Pellicano M, Schiariti M.

Cardiol Res. 2013 Feb;4(1):1-7. doi: 10.4021/cr251w. Epub 2013 Mar 8. Review.

4.

Regulation of Platelet Activation and Coagulation and Its Role in Vascular Injury and Arterial Thrombosis.

Tomaiuolo M, Brass LF, Stalker TJ.

Interv Cardiol Clin. 2017 Jan;6(1):1-12. doi: 10.1016/j.iccl.2016.08.001. Review.

5.

Anti-thrombotic agents derived from snake venom proteins.

Huang TF, Hsu CC, Kuo YJ.

Thromb J. 2016 Oct 4;14(Suppl 1):18. eCollection 2016. Review.

6.

A Novel Device for the Evaluation of Hemostatic Function in Critical Care Settings.

Ferrante EA, Blasier KR, Givens TB, Lloyd CA, Fischer TJ, Viola F.

Anesth Analg. 2016 Dec;123(6):1372-1379.

7.

The platelet: life on the razor's edge between hemorrhage and thrombosis.

Coller BS.

Transfusion. 2014 Sep;54(9):2137-46. doi: 10.1111/trf.12806. Epub 2014 Aug 5. No abstract available.

8.

Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives.

Dziewierz A, Rakowski T, Dudek D.

Ther Clin Risk Manag. 2014 Jul 18;10:567-76. doi: 10.2147/TCRM.S50002. eCollection 2014. Review.

9.

Eptifibatide-induced acute profound thrombocytopenia: a case report.

Graidis C, Golias C, Dimitriadis D, Dimitriadis G, Bitsis T, Dimitrelos I, Tsiakou A, Charalabopoulos K.

BMC Res Notes. 2014 Feb 25;7:107. doi: 10.1186/1756-0500-7-107.

10.

Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register.

Mrdovic I, Savic L, Lasica R, Krljanac G, Asanin M, Brdar N, Djuricic N, Marinkovic J, Perunicic J.

Eur Heart J Acute Cardiovasc Care. 2014 Mar;3(1):56-66. doi: 10.1177/2048872613514013. Epub 2013 Nov 21.

11.

A bumpy and winding but right path to domestic drug-eluting coronary stents.

Cho JY, Ahn Y, Jeong MH.

Korean Circ J. 2013 Oct;43(10):645-54. doi: 10.4070/kcj.2013.43.10.645. Review.

12.

Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.

Hess CN, Schulte PJ, Newby LK, Steg PG, Dalby AJ, Schweiger MJ, Lewis BS, Armstrong PW, Califf RM, van de Werf F, Harrington RA.

Eur Heart J Acute Cardiovasc Care. 2013 Sep;2(3):246-55. doi: 10.1177/2048872612474922.

13.

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.

Park S, Lee J, Lee SY, Bae JW, Hwang KK, Kim DW, Cho MC, Kim SM.

Korean Circ J. 2013 Aug;43(8):557-60. doi: 10.4070/kcj.2013.43.8.557. Epub 2013 Aug 31.

14.

Allergic reaction to abciximab with atypical manifestations.

Al-Moghairi AM, Abdullah MA.

J Saudi Heart Assoc. 2011 Apr;23(2):97-9. doi: 10.1016/j.jsha.2010.12.002. Epub 2011 Jan 6.

15.

Approach to the diagnosis and management of drug-induced immune thrombocytopenia.

Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, Kelton JG.

Transfus Med Rev. 2013 Jul;27(3):137-45. doi: 10.1016/j.tmrv.2013.05.005. Epub 2013 Jul 8. Review.

16.

Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Bledzka K, Smyth SS, Plow EF.

Circ Res. 2013 Apr 12;112(8):1189-200. doi: 10.1161/CIRCRESAHA.112.300570. Review.

17.

Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?

Berger PB, Williams JB, Hasselblad V, Chiswell K, Pieper KS, Califf RM.

J Interv Cardiol. 2013 Apr;26(2):123-30. doi: 10.1111/j.1540-8183.2013.12020.x. Epub 2013 Feb 5.

18.

High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI - The Tamip Study.

Balghith MA.

Heart Views. 2012 Jul;13(3):85-90. doi: 10.4103/1995-705X.102145.

19.

Translating from the rivers of Babylon to the coronary bloodstream.

Coller BS.

J Clin Invest. 2012 Nov;122(11):4293-9. doi: 10.1172/JCI66867. Epub 2012 Nov 1. No abstract available.

20.

Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.

Iqbal Z, Rana G, Cohen M.

Curr Cardiol Rev. 2012 Aug;8(3):181-91. Review.

Supplemental Content

Support Center